{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:36:58Z","timestamp":1788881818487,"version":"build-2803163510"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["2016-ER6304-02"],"award-info":[{"award-number":["2016-ER6304-02"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>There has been a concern that angiotensin receptor blockers (ARB) may increase myocardial infarction (MI) in hypertensive patients compared with other classes of anti-hypertensive drugs. Angiotensin-converting enzyme inhibitor (ACEI) is recommended as a first-line inhibitor of renin-angiotensin system (RASI) in patients with acute MI (AMI), but ARB is also frequently used to control blood pressure. This study investigated the association of ARB vs. ACEI with the long-term clinical outcomes in hypertensive patients with AMI. Among patients enrolled in the nationwide AMI database of South Korea, the KAMIR-NIH, 4,827 hypertensive patients, who survived the initial attack and were taking ARB or ACEI at discharge, were selected for this study. ARB therapy was associated with higher incidence of 2-year major adverse cardiac events, cardiac death, all-cause death, MI than ACEI therapy in entire cohort. After propensity score-matching, ARB therapy was still associated with higher incidence of 2-year cardiac death (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.20\u20132.14; <jats:italic>P<\/jats:italic> = 0.001), all-cause death (HR, 1.81; 95% CI, 1.44\u20132.28; <jats:italic>P<\/jats:italic> &lt; 0.001), and MI (HR, 1.76; 95% CI, 1.25\u20132.46; <jats:italic>P<\/jats:italic> = 0.001) than the ACEI therapy. It was concluded that ARB therapy at discharge in hypertensive patients with AMI was inferior to ACEI therapy with regard to the incidence of CD, all-cause death, and MI at 2-year. These data suggested that ACEI be a more appropriate RASI than ARB to control BP in hypertensive patients with AMI.<\/jats:p>","DOI":"10.1371\/journal.pone.0281460","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:42:14Z","timestamp":1678387334000},"page":"e0281460","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-9584","authenticated-orcid":true,"given":"Jae-Geun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4322-0703","authenticated-orcid":true,"given":"Seung-Jae","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-8165","authenticated-orcid":true,"given":"Song-Yi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Hyouk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Yung","family":"Boo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ho","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the KAMIR-NIH investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"pone.0281460.ref001","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2016.04.132","article-title":"ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure\u2014A network meta-analysis","volume":"217","author":"F Ricci","year":"2016","journal-title":"Int J Cardiol"},{"key":"pone.0281460.ref002","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"B Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0281460.ref003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"B Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0281460.ref004","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"JP Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"pone.0281460.ref005","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/01.CIR.95.12.2643","article-title":"Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial","volume":"95","author":"MA Pfeffer","year":"1997","journal-title":"Circulation"},{"key":"pone.0281460.ref006","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"MA Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"pone.0281460.ref007","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"O Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0281460.ref008","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pcad.2004.04.003","article-title":"The clinical use of angiotensin-converting enzyme inhibitors","volume":"47","author":"J Wong","year":"2004","journal-title":"Prog Cardiovasc Dis"},{"key":"pone.0281460.ref009","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"S Julius","year":"2004","journal-title":"Lancet"},{"key":"pone.0281460.ref010","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1253\/circj.CJ-16-0061","article-title":"Multicenter Cohort Study of Acute Myocardial Infarction in Korea- Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry","volume":"80","author":"JH Kim","year":"2016","journal-title":"Circ J"},{"key":"pone.0281460.ref011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.gheart.2018.08.004","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"13","author":"K Thygesen","year":"2018","journal-title":"Glob Heart"},{"key":"pone.0281460.ref012","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"G Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"pone.0281460.ref013","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1681\/ASN.2014040371","article-title":"Commentary on the 2014 BP guidelines from the panel appointed to the Eighth Joint National Committee (JNC 8)","volume":"25","author":"E Reisin","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"pone.0281460.ref014","doi-asserted-by":"crossref","first-page":"e001010","DOI":"10.1136\/openhrt-2019-001010","article-title":"Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction","volume":"6","author":"D Ko","year":"2019","journal-title":"Open Heart"},{"key":"pone.0281460.ref015","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1097\/CM9.0000000000000432","article-title":"Angiographic characteristics and in-hospital mortality among patients with ST-segment elevation myocardial infarction presenting without typical chest pain: an analysis of China Acute Myocardial Infarction registry","volume":"132","author":"CX Song","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"pone.0281460.ref016","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"PK Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"pone.0281460.ref017","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.116.025950","article-title":"Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction","volume":"135","author":"FH Messerli","year":"2017","journal-title":"Circulation"},{"key":"pone.0281460.ref018","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","article-title":"Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: Further evidence for the ARB-MI Paradox","volume":"135","author":"MH Strauss","year":"2017","journal-title":"Circulation"},{"key":"pone.0281460.ref019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"S Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"pone.0281460.ref020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"J Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"pone.0281460.ref021","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"J McMurray","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"pone.0281460.ref022","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40256-015-0140-5","article-title":"Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry","volume":"15","author":"PS Song","year":"2015","journal-title":"Am J Cardiovasc Drugs"},{"key":"pone.0281460.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2014.03.055","article-title":"Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker","volume":"114","author":"M Hara","year":"2014","journal-title":"Am J Cardiol"},{"key":"pone.0281460.ref024","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2018.08.038","article-title":"Other Korea Acute Myocardial Infarction Registry i. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention","volume":"277","author":"JK Byun","year":"2018","journal-title":"Atherosclerosis"},{"key":"pone.0281460.ref025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/0003319719884187","article-title":"ACE inhibitors versus ARBs in patients with NSTEMI with preserved LV systolic function who underwent PCI with new generation drug-eluting stents","volume":"71","author":"YH Kim","year":"2020","journal-title":"Angiology"},{"key":"pone.0281460.ref026","doi-asserted-by":"crossref","first-page":"e0242314","DOI":"10.1371\/journal.pone.0242314","article-title":"The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension","volume":"15","author":"AY Her","year":"2020","journal-title":"PLoS One"},{"key":"pone.0281460.ref027","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"MH Strauss","year":"2006","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:42:37Z","timestamp":1678387357000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281460"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"Lionetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0281460","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}